Agenus Newsroom

GSK Arexvy Protects From RSV Over Three Full Seasons

Seeking AlphaOct 8 08:32 ET

EXACT Therapeutics Partners With Agenus in Cancer Research

TipRanksOct 8 04:34 ET

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults

BenzingaSep 18 10:01 ET

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

BusinesswireSep 18 07:00 ET

Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results

MT NewswiresSep 9 15:02 ET

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to Be Presented in Oral Session at ESMO 2024

BusinesswireSep 9 07:30 ET

Agenus to Participate in September Investor Conferences

BusinesswireSep 3 07:30 ET

Agenus Analyst Ratings

BenzingaAug 14 08:57 ET · Ratings

B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating

MT NewswiresAug 14 07:58 ET · Ratings

Express News | Agenus Inc : B. Riley Cuts Target Price to $18 From $42

ReutersAug 13 23:57 ET

B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $18

Moomoo NewsAug 13 14:31 ET · Ratings

Agenus: Strong Clinical Potential Amidst Regulatory Challenges and Revised Market Entry Forecast

TipRanksAug 13 13:35 ET

Agenus Appoints New Director and Plans Equity Offering

TipRanksAug 8 17:17 ET

Agenus | 10-Q: Q2 2024 Earnings Report

SECAug 8 16:18 ET · Announcements

Agenus Q2 2024 GAAP EPS $(2.52) Misses $(1.07) Estimate, Sales $23.509M Miss $61.477M Estimate

BenzingaAug 8 07:19 ET

Earnings Flash (AGEN) AGENUS Reports Q2 Revenue $23.5M, Vs. Street Est of $63.5M

MT NewswiresAug 8 07:11 ET

Express News | Agenus Reports Second Quarter 2024 Operational and Financial Results

ReutersAug 8 07:00 ET

Agenus Announces Appointment of Tom Harrison to Board of Directors

BusinesswireAug 8 07:00 ET

Agenus 2Q Loss/Shr $2.52 >AGEN

Dow JonesAug 8 07:00 ET

Here Is the Next Potential Market Catalyst

Seeking AlphaAug 7 18:00 ET